. 2023 Feb 20;6(2):e230147. doi: 10.1001/jamanetworkopen.2023.0147

Table 3. Estimated Mean Group Differences Between Simvastatin and Placebo and Odds Ratios for the Secondary Outcomes.

Measure	Estimate (95% CI)^a	SMD (95% CI)	P value
MADRS remission	0.89 (0.28 to 2.8)	NA	.84
HamD-24	−0.39 (−3.29 to 2.5)	−0.06 (−0.51 to 0.39)	.79
GAD-7	−0.57 (−1.98 to 0.85)	−0.09 (−0.31 to 0.13)	.44
CGI	0.66 (0.31 to 1.43)	NA	.29
MMAS-4	0.10 (−0.18 to 0.38)	0.08 (−0.14 to 0.32)	.48
BMI	0.12 (−0.06 to 0.3)	0.02 (−0.01 to 0.06)	.18

Abbreviations: BMI, body mass index; CGI, Clinical Global Impression Scale; GAD-7, 7-item Generalized Anxiety Disorder Scale; HamD-24, 24-item Hamilton Rating Scale for Depression; MADRS, Montgomery-Åsberg Depression Rating Scale; MMAS-4, 4-item Morisky Medication Adherence Scale; NA, not applicable; SMD, standard mean difference.

^{^a}

Estimates are odds ratios for MADRS remission and CGI and mean differences for all other measures.